BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36108304)

  • 1. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
    Maese L; Loh ML; Choi MR; Lin T; Aoki E; Zanette M; Agarwal S; Iannone R; Silverman JA; Silverman LB; Raetz EA; Rau RE
    Blood; 2023 Feb; 141(7):704-712. PubMed ID: 36108304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of intramuscular recombinant Erwinia chrysanthemi asparaginase (JZP458) in patients with acute lymphoblastic leukemia.
    Lin T; Whigham T; Fernando I; Choi MR; Wang Q; Silverman JA
    Clin Transl Sci; 2023 May; 16(5):898-909. PubMed ID: 36929533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
    Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
    Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
    Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458).
    Lin T; Dumas T; Kaullen J; Berry NS; Choi MR; Zomorodi K; Silverman JA
    Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1503-1513. PubMed ID: 34310867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
    Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
    Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
    Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult Volunteers.
    Lin T; Hernandez-Illas M; Rey A; Jenkins J; Chandula R; Silverman JA; Choi MR
    Clin Transl Sci; 2021 May; 14(3):870-879. PubMed ID: 33278328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asparaginase
    Gao C; Ma X; Zhang Z; Lu Q; Ashby CR; Wei L; Chen ZS
    Drugs Today (Barc); 2022 Jun; 58(6):261-271. PubMed ID: 35670704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
    Burke MJ; Zalewska-Szewczyk B
    Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
    Figueiredo L; Cole PD; Drachtman RA
    Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
    Billett AL; Carls A; Gelber RD; Sallan SE
    Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
    Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
    Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM
    BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management.
    Sandley M; Angus J
    Leuk Lymphoma; 2023 Apr; 64(4):776-787. PubMed ID: 36781296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
    Larson RA; Fretzin MH; Dodge RK; Schiffer CA
    Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
    Feldman K; Aaronson K; Gu T; Ige K; Southworth E; Sanchez L; Stieglitz E
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30891. PubMed ID: 38311802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
    Duval M; Suciu S; Ferster A; Rialland X; Nelken B; Lutz P; Benoit Y; Robert A; Manel AM; Vilmer E; Otten J; Philippe N
    Blood; 2002 Apr; 99(8):2734-9. PubMed ID: 11929760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
    Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.